Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results

Share Name	Share Symbol	Market	Type
Nucryst Pharmaceuticals - Common Shares (MM)	NASDAQ:NCST	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Nucryst Pharmaceuticals - Common Shares (MM)

NASDAQ:NCST

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

1.77

01:00:00

Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results

21/07/2009 9:30pm

PR Newswire (US)

Nucryst (NASDAQ:NCST)
Historical Stock Chart

From Jul 2019 to Jul 2024

Wednesday, August 5, 2009 9:00 a.m. EDT PRINCETON, NJ, July 21 /PRNewswire-FirstCall/ -- NUCRYST Pharmaceuticals Corp. invites analysts and investors to participate in a briefing on Wednesday, August 5, with David B. Holtz, Interim President Chief Executive Officer, and Chief Financial Officer, regarding the Company's 2009 second quarter results. The briefing, via conference call, is set for 9:00 a.m. EDT. To participate, please call the toll-free number 1-800-731-5774. In addition to standard disclosure over wire services, a news release with the second quarter results will be posted on the NUCRYST web site prior to the call. To listen to the call live on the Internet, please go to http://www.nucryst.com/web_casts.htm. The briefing will be recorded and available for re-broadcast on demand for seven days by dialing 1-877-289-8525. Callers will need to provide the operator with the following reservation number: 21309904 followed by the number sign. An audio file of the call will also be archived on the NUCRYST web site. About NUCRYST Pharmaceuticals NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101, for use in medical devices and as an active pharmaceutical ingredient. Acticoat(TM) is a trademark of Smith & Nephew plc SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp. DATASOURCE: NUCRYST Pharmaceuticals Corp. CONTACT: David Wills, Gillian McArdle, Investor Relations, NUCRYST Pharmaceuticals Corp., (416) 504-8464,

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

NCST Nucryst Pharmaceuticals - Common Shares (MM)